arrow
T

Teresa Noviello

university of miami
H指数:12
被引数:421

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Transposable elements and homotypic niches drive immune dynamics and resistance in melanoma epigenetic-based immunotherapy

转座元件和同型微环境驱动黑色素瘤表观遗传基础免疫治疗的免疫动态和抗性

2026-08-070
OA
Circulating EV-microRNAs are dynamic biomarkers of resistance to therapeutic immunomodulation in metastatic melanoma

循环EV-miRNA是转移性黑色素瘤对治疗性免疫调节抵抗的动态生物标志物

2026-05-080
OAAI
Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study

NIBIT-epi-meso研究中肿瘤DNA甲基化亚型预测胸膜间皮瘤患者的免疫治疗结果

2026-04-270
PRE
DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy

DNA甲基化状态根据其免疫表型对胸膜间皮瘤细胞进行分类:对精准表观遗传治疗的启示

2025-02-180
OA
EPIGENETIC POTENTIATION OF ANTI-TUMOR IMMUNE RESPONSES USING VIRAL MIMICRY IN GLIOMAS
2024-11-110
PRE
FateAI: Analysis of circulating DNA fragmentomics with an artificial intelligence model for cancer screening
2024-04-050
PRE
MiR-449a antagonizes EMT through IL-6-mediated trans-signaling in laryngeal squamous cancer
2024-03-012
OAAI
Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches
2024-03-012
OAAI
Integrated molecular and multiparametric MRI mapping of high-grade glioma identifies regional biologic signatures
2023-09-285
OAAI
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial
2023-09-229
OAAI
Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients (Jun, 10.1007/s40618-023-02115-2, 2023)
2023-08-100
OAAI
Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients
2023-06-077
OAAI
Multi-parametric MRI maps regional heterogeneity of high grade glioma phenotypes
2023-04-040
PRE
Guadecitabine plus ipilimumab in unresectable melanoma: Five-year follow-up and correlation with integrated, multi-omic analysis in the NIBIT-M4 trial
2023-04-040
PRE
Multiregional sampling of high grade glioma identifies regional biologic signatures
2023-04-040
PRE
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy
2022-11-179
OAAI